Coeptis Therapeutics Holdings has completed its business combination with Bull Horn Holdings Corp (BHSE), now trading on Nasdaq under the symbols COEP and COEPW. This merger positions Coeptis as a leader in cancer cell therapy, following the in-licensing of SNAP-CAR technology. Approximately 19.5 million shares are outstanding, with former Coeptis shareholders owning 88% of the combined entity. The transaction aims to enhance visibility and liquidity for investors, marking a pivotal step toward long-term growth in the biotech sector.
Coeptis Therapeutics has entered an exclusive license agreement with the University of Pittsburgh for the SNAP-CAR technology, allowing for a programmable CAR T cell therapy targeting multiple cancer antigens. This innovative approach aims to broaden treatment options for hematologic malignancies and solid tumors like breast and ovarian cancer. The SNAP-CAR platform is poised to enhance CAR T therapies by potentially reducing toxicity and addressing cancer relapse, marking a significant advance in Coeptis' cell therapy product portfolio.
The Major Arena Soccer League announced that Brazilian football legend Ronaldinho is joining as a Co-Owner of an expansion team. This partnership aims to enhance the league's global appeal and boost its popularity in the USA and beyond. Ronaldinho, known for his impressive career and accolades, including two FIFA World Player of the Year awards, expressed excitement for this venture. The league features 14 teams across the United States and Mexico, playing fast-paced indoor soccer. More details about the new team will be released soon.
Coeptis Therapeutics, Inc. (OTC PINK: COEP) and Bull Horn Holdings Corp. (Nasdaq: BHSE) have announced a definitive merger agreement, with Coeptis becoming a wholly-owned subsidiary of Bull Horn. The transaction, valued at $175 million, is expected to close in Q3 2022, pending regulatory and shareholder approvals. Coeptis focuses on innovative cell therapy platforms for cancer, including CD38-GEAR-NK and CD38-Diagnostic. David Mehalick will continue as CEO, while Chris Calise joins the Board. The merged entity will be rebranded as Coeptis Therapeutics Holdings, Inc., to list under the ticker symbol 'COEP'.
Bull Horn Holdings Corp. (NASDAQ: BHSE) announced it received a notice from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. The company cited the need for additional time to review its financial statements as the reason for the delay. Although the notice does not immediately affect trading, the company has 60 days from September 2, 2021, to file the report to regain compliance. Non-compliance may lead to delisting procedures. The company is working diligently to submit the Form 10-Q and restore compliance.
Bull Horn Holdings Corp. (NASDAQ: BHSE) has received a notice from Nasdaq due to the late filing of its Quarterly Report on Form 10-Q for Q1 2021. The company stated it required additional time to adjust its financial statements following SEC guidance on warrant accounting. The notice does not immediately affect trading but mandates the filing of the 10-Q within 60 days from May 28, 2021. Failure to comply may lead to suspension or delisting. The company is actively working to complete the report and regain compliance by the deadline.